You know the statistics about how hard it is to bring a new drug to market. And yet, because of your passionate pursuit of a novel therapy, here you are. Despite the greater challenges emerging biotech companies face. Parexel® Biotech is here to help you solve them the right way, so you get your best shot at success.
Other content in this Stream
Parexel’s Anita Nelsen, SVP, Translational Medicine and Michelle Hoiseth, Chief Data Officer, Corporate VP speak with Ashley Druckenmiller about caring with her two sons with hemophilia and the benefi
Learn more about how to address operational challenges that come with harnessing RWD.
Amy McKee, Vice President Regulatory Consulting Services, addresses some of the most common misconceptions about working with the FDA.
Learn about the benefits that real-world evidence (RWE) can bring to small & mid-size biotech companies.
Enabling patients to participate in clinic trials from home is both important to maintain patient safety and data quality in ongoing trials and critical for many new trials as we plan for COVID-19.
In this blog, Parexel regulatory and strategy experts tackle the question of how we can ensure that worthy innovations in the biotech pipeline make it to patients sooner.
Learn more about what to look for in the right CRO partner to overcome logistical and operational challenges in cell and gene therapy product development.
Parexel precision medicine experts Angela Qu and Arlene Hughes join host Alberto Grignolo to discuss how biotech companies can incorporate precision medicine into their development plans.
Parexel’s Andreas Reiff, VP, Global TA Head, Inflammation/Immunology talks with Julie Stover, Senior Director, Solution Consulting, also from Parexel, about her journey being diagnosed with Ankylosing
Collectively, rare diseases affect over 30 million Americans. The Orphan Drug Act (ODA), which provides the statutory basis for FDA to designate a drug or biologic agent as a therapy for a...
The pharmaceutical industry is inundated with a plethora of communications about data integrity. Let's look at at one of these situations where applicant holders face these issues successfully.
Hear firsthand from Monica about her personal journey as a clinical trial participant to understand the value of easing patient burden
James Anthony, SVP, Global Head Biotech and Graciela Rácaro, SVP, Global Head, Biotech Operations, both from Parexel, discuss how Parexel Biotech has been built to meet customer and patient needs
For biotech companies, precision medicine holds tremendous promise for innovation – for newly designed drugs, new technologies for drug delivery, and engineered cell or gene therapies.
Learn about five economical and efficient ways to make early phase trials both patient-centric and more effective.
Three strategies that apply multidisciplinary solutions earlier in the development process to reduce failures and accelerate CNS drug development.